SUNNYVALE, Calif.--(BUSINESS WIRE)--Theron Pharmaceuticals, Inc., a preclinical stage Biotechnology company developing a best-in-class long acting M3 muscarinic antagonist (LAMA) targeting the multi-billion dollar chronic obstructive pulmonary disease (COPD) and asthma markets, announced today that the company will present a poster highlighting Theron’s lead development candidate, TRN-157, at the American Thoracic Society (ATS) Conference May 13th – 18th, 2011 in Denver, Colorado.
